Selecta Biosciences, Inc.

480 Arsenal Street
Building One

Watertown, MA  02472

Tel: (617) 923.1400


Leadership:
Werner Cautreels, Ph.D.
CEO


Website:
www.selectabio.com

Selecta Biosciences, Inc.

Flagship Partners:  Ed Kania
Initial Investment: 
2008
Status: 
Private

Selecta Biosciences is a clinical-stage biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications. Selecta was founded based on complementary research by three academic pioneers, the technology innovations of Professors Robert Langer (M.I.T.) and Omid Farokhzad (Harvard Medical School) combined with the immunological insights of Professor Ulrich von Andrian (Harvard Medical School). Selecta's proprietary Synthetic Vaccine Particle (SVP™) platform creates a new paradigm in vaccine development, enabling completely new therapeutic and prophylactic applications while offering the potential of improved efficacy and safety profiles.

Ed Kania is on the Board of Directors.